A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.
Kollmorgen G, et al. Among authors: hirzel k.
Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7.
Sci Rep. 2017.
PMID: 29273809
Free PMC article.